Welcome to my homepage at the University of South Australia. I am located at City West Campus, where I am Associate Professor at Clinical and Health Sciences. I am currently the Course Coordinator of Pharmacokinetics and Biopharmaceutics, and Frontiers in Pharmacy Practice and Pharmaceutical Science courses, and co-cordinate the Pharmacokinetic-Pharmacodynamic modelling course.
My research interests include the optimisation of pharmacotherapeutic treatment of patients through understanding the factors that are responsible for differences in response to medicines between people. This research is primarily focussed on identifying the pharmacokinetic and pharmacodynamic factors which govern variability in drug response. My work... Read more
About me
Welcome to my homepage at the University of South Australia. I am located at City West Campus, where I am Associate Professor at Clinical and Health Sciences. I am currently the Course Coordinator of Pharmacokinetics and Biopharmaceutics, and Frontiers in Pharmacy Practice and Pharmaceutical Science courses, and co-cordinate the Pharmacokinetic-Pharmacodynamic modelling course.
My research interests include the optimisation of pharmacotherapeutic treatment of patients through understanding the factors that are responsible for differences in response to medicines between people. This research is primarily focussed on identifying the pharmacokinetic and pharmacodynamic factors which govern variability in drug response. My work aims to employ pharmacometric analysis (modelling and simulation) as a tool to translate basic and clinical research into improved pharmacotherapetic use. Pharmacometrics is the science which deals with the quantitative description of disease, drug effects and variability. The rapidly expanding area of pharmacogenomics is also providing a constant source of genetic differences between people which have major impacts on drug effects and pharmacokinetics. Pharmacometric analyses quantify drug, disease and trial information to aid efficient drug use, development, and regulatory decisions. The strength of such analyses is the ability to integrate knowledge from prior understanding, related compounds and biology, together with the ability to include both richly sampled data and more limited/incomplete data typically unusable in traditional statistical approaches. This area has traditionally been poorly understood by mainstream biomedical researchers. However, this is now changing and increasingly researchers, regulatory authorities and funding bodies are recognizing the power that pharmacometric analyses provide.
I am immediate past President of the Population Approach Group of Australia and New Zealand (PAGANZ) which is the peak body representing pharmacometrics in Australasia, and until December 2018 co-chair of the Drug Disposition and Response special interest group of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) of which I have been a member since 1993. I have won awards for my teaching at UniSA, including the UniSA Supported Teacher (2011 and 2012), and the Student-nominated “Excellence in teaching” in 2017. As of 2024, I am the National Chair of the CSIRO Health and Medical Human Research Ethics Committee.
Some other information about me:
CSIRO
Population Approach Group of Australia and New Zealand (www.paganz.org)
Bellberry Inc Human Research Ethics Committee
Children, Youth and Women’s Health Service
Australasian Society of Clinical and Experimental Pharmacologists andToxicologists (ASCEPT)
Therapeutic Goods Adminstration
Editorial Board membership:
Adelaide Pharmacology Group
Invited presenations
About me
CSIRO
Population Approach Group of Australia and New Zealand (www.paganz.org)
Bellberry Inc Human Research Ethics Committee
Children, Youth and Women’s Health Service
Australasian Society of Clinical and Experimental Pharmacologists andToxicologists (ASCEPT)
Therapeutic Goods Adminstration
Editorial Board membership:
Adelaide Pharmacology Group
Invited presenations
About me
Doctor of Philosophy The University of Adelaide
Bachelor of Science The University of Adelaide
Bachelor of Science The University of Adelaide
The Australian Centre for Pharmacometrics (ACP)
http://www.therapeuticinnovation.com.au/Research_and_Development/Virtual_Pharma_Pharmaceutical_Developability_Network/Pharmacometrics.aspx
I am leader of the Australian Centre for Pharmacometrics research group. This is result of a successful application to the Translating Health Discovery section of the national Super Science Initiative. The role of Australian Centre for Pharmacometrics is to facilitate training and education in pharmacometrics and increase the utilization of such analyses in biomedical research on a national scale. It will facilitate drug development and biomedical research nationally by providing a high-end computing facility and pharmacometric expertise which can... Read more
Research
Excludes commercial-in-confidence projects.
Product Evaluation Services – Pop PK Evaluation for PM-2019-00471-1-6, Therapeutic Goods Administration, 04/04/2019 - 01/06/2024
Medical and advisory services, Therapeutic Goods Administration, 01/01/2014 - 31/12/2020
Model based methods to predict clinical drug exposure from formulation characteristics, Mayne Pharma Pty Ltd, 10/07/2017 - 09/07/2020
Development of a population PCK model based on doryx biostudy data, Mayne Pharma Pty Ltd, 03/08/2015 - 18/12/2016
Pimobendan Bioequivalence Power Ananysis, Luoda Pharma Pty Ltd, 20/06/2016 - 30/09/2016
Development of Pharmacometric Models of the Drug Itraconazole, Mayne Pharma Pty Ltd, 29/01/2016 - 30/09/2016
Research
Research outputs for the last seven years are shown below. Some long-standing staff members may have older outputs included. To see earlier years visit ORCID, ResearcherID or Scopus
Open access indicates that an output is open access.
| Year | Output |
|---|---|
| 2019 |
Open access
11
9
1
|
| 2019 |
Open access
8
8
|
| 2016 |
8
14
|
| 2016 |
Open access
|
| 2008 |
119
100
|
| Year | Output |
|---|---|
| 2024 |
Open access
|
| 2022 |
Open access
7
4
|
| 2022 |
Open access
6
4
150
|
| 2022 |
Open access
4
3
2
|
| 2022 |
Open access
11
9
2
|
| 2021 |
Open access
1
1
5
|
| 2021 |
4
4
1
|
| 2020 |
Open access
16
19
1
|
| 2020 |
Open access
14
12
1
|
| 2020 |
Open access
2
2
2
|
| 2019 |
Open access
11
9
1
|
| 2019 |
Open access
3
3
7
|
| 2019 |
Open access
9
8
4
|
| 2019 |
7
7
4
|
| 2019 |
Open access
8
8
|
| 2018 |
Open access
5
5
|
| 2018 |
2
2
1
|
| 2017 |
225
186
11
|
| 2017 |
Open access
9
10
1
|
| 2017 |
Open access
8
8
3
|
| 2017 |
Open access
7
7
10
|
| 2017 |
Open access
4
5
|
| 2017 |
Open access
6
6
|
| 2017 |
29
29
3
|
| 2016 |
86
92
6
|
| 2016 |
65
30
1
|
| 2016 |
28
24
14
|
| 2016 |
Open access
8
5
|
| 2016 |
8
14
|
| 2016 |
Open access
27
27
15
|
| 2016 |
6
4
7
|
| 2016 |
Open access
35
27
1
|
| 2016 |
Open access
|
| 2016 |
26
26
1
|
| 2016 |
20
17
2
|
| 2015 |
Open access
6
5
|
| 2015 |
Open access
80
69
12
|
| 2015 |
Open access
16
12
|
| 2014 |
6
5
1
|
| 2014 |
7
7
|
| 2014 |
Open access
4
4
|
| 2014 |
Open access
7
7
|
| 2014 |
16
17
|
| 2014 |
Open access
5
4
|
| 2013 |
Open access
18
18
|
| 2012 |
Open access
47
42
|
| 2012 |
Open access
11
10
|
| 2011 |
Open access
37
31
|
| 2011 |
13
13
|
| 2010 |
24
22
|
| 2010 |
Open access
28
26
|
| 2010 |
3
3
|
| 2008 |
55
48
|
| 2008 |
24
25
|
| 2008 |
119
100
|
| 2008 |
90
77
|
Research
The Australian Centre for Pharmacometrics (ACP)
http://www.therapeuticinnovation.com.au/Research_and_Development/Virtual_Pharma_Pharmaceutical_Developability_Network/Pharmacometrics.aspx
I am leader of the Australian Centre for Pharmacometrics research group. This is result of a successful application to the Translating Health Discovery section of the national Super Science Initiative. The role of Australian Centre for Pharmacometrics is to facilitate training and education in pharmacometrics and increase the utilization of such analyses in biomedical research on a national scale. It will facilitate drug development and biomedical research nationally by providing a high-end computing facility and pharmacometric expertise which can be accessed by ACP members across Australia and New Zealand: UniSA, Monash University, University of Queensland, University of Sydney, Otago University and Auckland University.
External engagement & recognition
| Organisation | Country |
|---|---|
| Aalborg University | DENMARK |
| AstraZeneca R&D Lund | SWEDEN |
| Biocompatibles UK Ltd | UNITED KINGDOM |
| Copenhagen Business School | DENMARK |
| Copenhagen University | DENMARK |
| Copenhagen University Hospital | DENMARK |
| Curtin University | AUSTRALIA |
| Flinders University | AUSTRALIA |
| George Institute for Global Health | AUSTRALIA |
| Griffith University | AUSTRALIA |
| Institute of Medical and Veterinary Science | AUSTRALIA |
| Luoda Pharma | AUSTRALIA |
| Mayne Pharma Pty Ltd | AUSTRALIA |
| Monash University | AUSTRALIA |
| Norwegian University of Science and Technology | NORWAY |
| Nycomed Pharma | DENMARK |
| Ohio State University | UNITED STATES |
| Oklahoma State University - Stillwater | UNITED STATES |
| Postgraduate Institute of Medical Education and Research | INDIA |
| Projections Research Inc. | UNITED STATES |
| Royal Adelaide Hospital | AUSTRALIA |
| SA Pathology | AUSTRALIA |
| St Vincents Hospital | UNITED STATES |
| The Byrne Surgery, Specialist Drug and Alcohol Practice, Redfern, New South Wales | AUSTRALIA |
| The Danish University of Pharmaceutical Sciences | DENMARK |
| The Royal Marsden NHS Foundation Trust | UNITED KINGDOM |
| University Children's Hospital Basel | SWITZERLAND |
| University of Adelaide | AUSTRALIA |
| University of Auckland | NEW ZEALAND |
| University of Copenhagen | DENMARK |
| University of East Anglia | UNITED KINGDOM |
| University of Melbourne | AUSTRALIA |
| University of New South Wales | AUSTRALIA |
| University of Otago | NEW ZEALAND |
| University of Oxford | UNITED KINGDOM |
| University of Queensland | AUSTRALIA |
| University of Sharjah | UNITED ARAB EMIRATES |
| University of South Australia | AUSTRALIA |
| University of Sydney | AUSTRALIA |
| University of Turin | ITALY |
| Victoria University | AUSTRALIA |
| Western Sydney University | AUSTRALIA |
External engagement & recognition
| Engagement/recognition | Year |
|---|---|
Health and Medical Human Research Ethics CommitteeCSIRO |
2023 |
Executive EditorBritish Journal of Clinical Pharmaology |
2023 |
HREC review committee memberBellberry Inc |
2023 |
Organising Committee MemberPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2023 |
Workshop facilitatorPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2023 |
Executive EditorBritish Journal of Clinical Pharmaology |
2022 |
HREC review committee memberBellberry Inc |
2022 |
PresidentPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2022 |
Workshop facilitatorPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2022 |
Executive EditorBritish Journal of Clinical Pharmaology |
2021 |
HREC review committee memberBellberry Inc |
2021 |
PresidentPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2021 |
Executive EditorBritish Journal of Clinical Pharmaology |
2020 |
HREC review committee memberBellberry Inc |
2020 |
PresidentPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2020 |
Executive EditorBritish Journal of Clinical Pharmaology |
2019 |
HREC review committee memberBellberry Inc |
2019 |
PresidentPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2019 |
Co-chair, Drug Disposition and Response special interest groupAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2018 |
Executive MemberAdelaide Pharmacology Group, University of Adelaide |
2018 |
Expert AdvisorAustralian Committee on Medicines |
2018 |
HREC review committee memberBellberry Inc |
2018 |
Member, Australian Drug Evaluation Committee (Pharmaceutical Sub Committee)Therapeutic Goods Administration, Department of Health, Australian Government |
2018 |
PresidentPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2018 |
PresidentPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2018 |
Co-chair, Drug Disposition and Response special interest groupAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2017 |
Executive MemberAdelaide Pharmacology Group, University of Adelaide |
2017 |
Expert AdvisorAustralian Committee on Medicines |
2017 |
HREC review committee memberBellberry Inc |
2017 |
Member, Australian Drug Evaluation Committee (Pharmaceutical Sub Committee)Therapeutic Goods Administration, Department of Health, Australian Government |
2017 |
Member, Children, Youth and Women Health Service Drug TrialsDrug and Therapeutics Committee, SA Health, Government of South Australia |
2017 |
PresidentPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2017 |
PresidentPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2017 |
Workshop FacilitatorPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2017 |
Co-chair, Drug Disposition and Response special interest groupAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2016 |
Executive memberPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2016 |
Executive MemberAdelaide Pharmacology Group, University of Adelaide |
2016 |
HREC review committee memberBellberry Inc |
2016 |
local Organising Committee memberWorld Congress on Pharmacometrics (WCoP) |
2016 |
Member, Australian Drug Evaluation Committee (Pharmaceutical Sub Committee)Therapeutic Goods Administration, Department of Health, Australian Government |
2016 |
Member, Children, Youth and Women Health Service Drug TrialsDrug and Therapeutics Committee, SA Health, Government of South Australia |
2016 |
Organised symposia and chaired sessionAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2016 |
Organiser and Session ChairAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2016 |
Co-chair, Drug Disposition and Response special interest groupAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2015 |
Executive memberPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2015 |
Executive MemberAdelaide Pharmacology Group, University of Adelaide |
2015 |
HREC review committee memberBellberry Inc |
2015 |
Member, Australian Drug Evaluation Committee (Pharmaceutical Sub Committee)Therapeutic Goods Administration, Department of Health, Australian Government |
2015 |
Member, Children, Youth and Women Health Service Drug TrialsDrug and Therapeutics Committee, SA Health, Government of South Australia |
2015 |
Workshop FacilitatorPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2015 |
Co-chair, Drug Disposition and Response special interest groupAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2014 |
Executive memberPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2014 |
Executive MemberAdelaide Pharmacology Group, University of Adelaide |
2014 |
HREC review committee memberBellberry Inc |
2014 |
Member, Australian Drug Evaluation Committee (Pharmaceutical Sub Committee)Therapeutic Goods Administration, Department of Health, Australian Government |
2014 |
Member, Children, Youth and Women Health Service Drug TrialsDrug and Therapeutics Committee, SA Health, Government of South Australia |
2014 |
Organised symposia and chaired sessionAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2014 |
Organiser and Session ChairAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2014 |
Co-chair, Drug Disposition and Response special interest groupAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2013 |
Executive memberPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2013 |
Executive MemberAdelaide Pharmacology Group, University of Adelaide |
2013 |
HREC review committee memberBellberry Inc |
2013 |
Member, Pharmaceutical SubcommitteeAmerican College of Preventive Medicine (ACPM) |
2013 |
Member, Australian Drug Evaluation Committee (Pharmaceutical Sub Committee)Therapeutic Goods Administration, Department of Health, Australian Government |
2013 |
Member, Children, Youth and Women Health Service Drug TrialsDrug and Therapeutics Committee, SA Health, Government of South Australia |
2013 |
Organised symposia and chaired sessionAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2013 |
Organiser and Session ChairAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2013 |
Co-chair, Drug Disposition and Response special interest groupAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2012 |
Executive memberPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2012 |
Executive MemberAdelaide Pharmacology Group, University of Adelaide |
2012 |
Member, Australian Drug Evaluation Committee (Pharmaceutical Sub Committee)Therapeutic Goods Administration, Department of Health, Australian Government |
2012 |
Member, Children, Youth and Women Health Service Drug TrialsDrug and Therapeutics Committee, SA Health, Government of South Australia |
2012 |
Organised symposia and chaired sessionAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2012 |
Organiser and Session ChairAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2012 |
Co-chair, Drug Disposition and Response special interest groupAustralasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) |
2011 |
Executive MemberAdelaide Pharmacology Group, University of Adelaide |
2011 |
Member, Australian Drug Evaluation Committee (Pharmaceutical Sub Committee)Therapeutic Goods Administration, Department of Health, Australian Government |
2011 |
Member, Children, Youth and Women Health Service Drug TrialsDrug and Therapeutics Committee, SA Health, Government of South Australia |
2011 |
Member, local organising committeeAustralasian Pharmaceutical Science Association (APSA) |
2011 |
Executive MemberAdelaide Pharmacology Group, University of Adelaide |
2010 |
Member, Australian Drug Evaluation Committee (Pharmaceutical Sub Committee)Therapeutic Goods Administration, Department of Health, Australian Government |
2010 |
Member, Children, Youth and Women Health Service Drug TrialsDrug and Therapeutics Committee, SA Health, Government of South Australia |
2010 |
Workshop FacilitatorPopulation Approach Group of Australia and New Zealand (PAGANZ) |
2010 |
Invited presenations
CSIRO
Population Approach Group of Australia and New Zealand (www.paganz.org)
Bellberry Inc Human Research Ethics Committee
Children, Youth and Women’s Health Service
Australasian Society of Clinical and Experimental Pharmacologists andToxicologists (ASCEPT)
Therapeutic Goods Adminstration
Editorial Board membership:
Adelaide Pharmacology Group
Teaching & student supervision
Teaching & student supervision
Supervisions from 2010 shown
| Thesis title | Student status |
|---|---|
| A computational approach to improve the prediction of fraction unbound to enhance pharmacokinetic (PK) and biopharmaceutic models | Current |
| Developing strategies to promote the use of treat to target strategies with conventional synthetic disease modifying anti-rheumatic drugs in patients with early rheumatoid arthritis | Current |
| Development of ex vivo models to predict the efficacy of disease modifying agents in rheumatoid arthritis | Current |
| Disposition of rosiglitazone in the feto-maternal unit | Completed |
| Individualisation of leflunomide dosing in rheumatoid arthritis patients | Completed |
| Investigating pharmacometric approaches to individualised medicine in autoimmune diseases | Completed |
| Monitoring post-exertional fatigue through the maximal rate of heart rate increase during submaximal exercise | Completed |
| Pharmacometric methodologies and their use for lenalidomide drug development in chronic lymphocytic leukaemia | Completed |
| Population-based models of the effect of food and pH on oral drug absorption | Completed |
